Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77

Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol (2014) 3.73

Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20

Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86

Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86

Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03

Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci (2013) 2.00

Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst (2015) 1.77

A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64

Inhibitory effects of baicalin on orthotopic xenografts of colorectal cancer cells that are deficient in a mismatch repair gene in nude mice. Int J Colorectal Dis (2012) 1.39

Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol (2011) 1.34

Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett (2011) 1.12

Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov (2013) 1.10

Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol (2011) 0.96

Aspirin and colorectal cancer: back to the future. Clin Cancer Res (2013) 0.95

History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol (2013) 0.95

The history of Lynch syndrome. Fam Cancer (2013) 0.94

Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89

Chemoprevention in Lynch syndrome. Fam Cancer (2013) 0.86

Drug therapy for hereditary cancers. Hered Cancer Clin Pract (2011) 0.85

Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) (2012) 0.84

Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c.C1528T mutation carriers and their mutation-negative sisters. Fam Cancer (2010) 0.83

Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? Fam Cancer (2013) 0.82

Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? ScientificWorldJournal (2012) 0.81

Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin Cancer Res (2010) 0.81

Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives. PLoS Curr (2013) 0.80

Advances in the study of Lynch syndrome in China. World J Gastroenterol (2015) 0.80

Aspirin and familial adenomatous polyposis: coming full circle. Cancer Prev Res (Phila) (2011) 0.80

Chemoprevention of hereditary colon cancers: time for new strategies. Nat Rev Gastroenterol Hepatol (2016) 0.80

Tumor strengths and frailties: Aspiring to prevent colon cancer. Nat Med (2012) 0.78

Taking the starch out of hereditary colorectal cancer. Lancet Oncol (2012) 0.78

Integrating genetic and genomic information into effective cancer care in diverse populations. Ann Oncol (2013) 0.78

A systematic review of aspirin in primary prevention: is it time for a new approach? Am J Cardiovasc Drugs (2015) 0.78

Hereditary Colorectal Cancer: Genetics and Screening. Surg Clin North Am (2015) 0.77

Endoscopic and surgical management of hereditary nonpolyposis colorectal cancer. Clin Colon Rectal Surg (2012) 0.77

Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice. Gut (2014) 0.77

Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer Prev Res (Phila) (2014) 0.77

Chemoprevention of colorectal cancer. Dig Dis (2014) 0.76

Chemoprevention in the lynch syndrome: what can we do? Gastroenterology (2009) 0.76

Pharmacological and dietary prevention for colorectal cancer. BMC Surg (2013) 0.76

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2009) 0.76

Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol (2015) 0.76

Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology (2016) 0.75

Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. Cancer Prev Res (Phila) (2017) 0.75

Aspirin, salicylates and cancer: report of a meeting at the Royal Society of Medicine, London, 23 November 2010. Ecancermedicalscience (2011) 0.75

Manipulation of DNA Repair Proficiency in Mouse Models of Colorectal Cancer. Biomed Res Int (2016) 0.75

Aspirin and decreased colon cancer risk: challenges interpreting a large prospective trial. J Adv Pract Oncol (2012) 0.75

Chemoprevention in patients with genetic risk of colorectal cancers. Colorectal Cancer (2012) 0.75

Chemoprevention of endometrial cancer in Lynch syndrome: a step forward. Cancer Prev Res (Phila) (2013) 0.75

Paraoxonase-1 and arylesterase activities in patients with colorectal cancer. Int J Clin Exp Med (2015) 0.75

Recent advances in understanding Lynch syndrome. F1000Res (2016) 0.75

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2009) 0.75

Effect of aspirin on tumour cell colony formation and evolution. J R Soc Interface (2017) 0.75

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23

Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81

Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet (2007) 9.88

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93

Colorectal cancer. Lancet (2010) 8.36

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65

Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62

Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42

Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut (2010) 6.34

A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25

Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91

Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70

The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol (2009) 4.94

Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med (2003) 4.88

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 4.82

GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54

Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19

Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ (2012) 4.19

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol (2009) 4.18

New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09

Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99

Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94

Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet (2007) 3.93

ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet (2008) 3.90

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86